Xpert Respiratory Panel
Cepheid · Decision date Sep 25, 2026
What did the FDA decide?
Cepheid received a substantially equivalent (SESE) determination for the Xpert Respiratory Panel under 510(k) K261336, with a decision date of September 25, 2026, in the microbiology specialty under product code QOF. The submission sought clearance by demonstrating substantial equivalence to the QIAstat-Dx Respiratory Panel Plus (K233100) for use on GeneXpert Instrument Systems. SESE denotes 510(k) clearance, not premarket approval.
The panel is a qualitative multiplexed in vitro diagnostic that detects and identifies DNA and RNA from listed respiratory bacteria and viruses, including SARS-CoV-2, in nasopharyngeal swab specimens from individuals with signs and symptoms of respiratory tract infection. It runs on GeneXpert Dx, Infinity and Touchscreen systems with specified software versions, and is labeled for prescription use only. The source does not record performance data, so comparative analytical results remain unknown.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Sep 25, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261336
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Cepheid
- Product code
- QOF
- Decision code
- SESE
- Decision date
- Sep 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents.
FDA decision timeline
K261336 received
Application receipt date recorded by FDA.
K261336 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QOF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| GenMark Diagnostics, Inc. | 510(k) clearance | Oct 30, 2026 | FDA | |
Xpert Xpress CoV-2/Flu plusK263333 | Cepheid | 510(k) clearance | Oct 22, 2026 | FDA |
Xpert Xpress CoV-2/Flu plusK263120 | Cepheid | 510(k) clearance | Oct 2, 2026 | FDA |
| Biofire Diagnostics | 510(k) clearance | Sep 22, 2026 | FDA | |
| Baebies, Inc. | 510(k) clearance | Sep 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cepheid
- Headquarters
- Not reported
- Brand website
- cepheid.com
- FDA applicant address
- Sunnyvale, CA
Sources and methodology
- Original FDA record: K261336
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

